Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
After looking at Yahoo it looks to me like Praetorian is completely out.
I think there would have been SEC filings to reflect that. I sent a note, will let you know if I find out anything. Probably by e-mail though.
I did not realize whose site I was reading until after I spent some time looking around. Interesting approach...
http://adventuresincapitalism.com/page/Investment-Strategy.aspx
It would have cost them a few thousand dollars to have a decent site developed, can't imagine why it hasn't been done already. Makes them look incompetent, imo.
Helicos BioSciences Announces Strategic Focus on Diagnostics Markets and Operational Restructuring
Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that, as part of the Company’s previously disclosed efforts to consider alternatives to its existing long-term strategy, it is in the process of implementing a strategic shift to focus the business on the diagnostics markets. In connection with this effort, the Company has committed to a consolidation and reorganization of its operations in order to reduce operating costs. This restructuring plan has resulted in the elimination of approximately 40 positions during the current fiscal quarter. Approximately half of the Company’s 40 remaining employees are supported by NIH funding on research designed to further improve Helicos’ proprietary DNA and RNA single molecule sequencing technology.
“In our first quarter 2010 regulatory filings, we stated that we were considering alternatives to our existing long-term strategic focus, including the repositioning of the company in the genetic analysis markets” stated Ron Lowy, President and Chief Executive Officer. “During this process, we have engaged a variety of consultants in the genomic research, services and diagnostics industries to evaluate available alternatives and, as a result of this evaluation, we believe that our proprietary technology is uniquely suited for the diagnostics markets. In particular, our technology’s ability to sequence DNA and RNA directly is well positioned for applications in molecular diagnostics, as it provides a direct path from patient specimen to result, and minimizes sample preparation costs. Furthermore, we believe the large opportunity for diagnostics sequencing applications is in its infancy, with relatively limited competition from major sequencing companies, which we believe are less capable for diagnostics applications.”
"One of the key growth drivers in the molecular diagnostics market has been the increased demand from both patients and physicians for assays that can inform decisions concerning personalized healthcare. We believe that Helicos' technology is capable of meeting this need today. This was recently exemplified in a study published in the journal The Lancet, in which sequencing data generated on the Helicos® Genetic Analysis System provided personalized and actionable information regarding an individual's health and disease risk." added Mr. Lowy.
Going forward, Helicos plans to continue to support its current installed base with collaborative activities, reagent supply and service support while shifting a significant portion of its resources towards the development of its diagnostics strategy and related technology, applications and commercialization plans.
“We thank all of our employees both past and present for their contribution to the development of Helicos’ technology which, we believe, provides Helicos with unique advantages in the molecular diagnostics marketplace” said Mr. Lowy.
The Company encourages investors to review Helicos’ Annual Report on Form 10-K for the fiscal year ended December 31, 2009 as filed with the SEC on April 15, 2010 together with the Company’s Quarterly Report on Form 10-Q for the first fiscal quarter 2010 as filed with the SEC on May 17, 2010. These reports include disclosures regarding the Company’s liquidity position, financing needs as well as additional disclosures regarding other risks and uncertainties faced by Helicos.
About Helicos BioSciences:
Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing, tSMS(TM), technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of two $1,000 genome grants and committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800. For more information, please visit www.helicosbio.com.
Hello MrMate. I think plums may have posted once or twice at SI but I am not 100% sure it was him and nothing has been heard from that poster since. So your guess is as good as mine. Recent developments are encouraging, imo.
Best,
tsl
I know...but the bonuses...well, who could resist? <g>
I got a job at Goldman Sachs. For fun, we go out at lunchtime, ride the train and steal wallets. Then we go back to the office and do it in size. To our customers.
JK.
Well...I can think of one person who will be happy to read that. And it isn't me.
I think we may pause a bit here but not for long.
Seems like a good idea. Will be interesting to see how MMG consolidates here.
You're buying the Dom Perignon, in that case. <g>
Your call was good if a little early, but yeah, I've been watching for a breakout since December too. The technicals and fundamentals were in alignment and the volume is showing us power in this move that must be respected, imo. That said, a rise at this angle could well be followed by a sharp pullback but not clear from what level and to what level at this point. Maybe test the .95 level to confirm it as support. We will see...
I'll take that under advisement!
Whatever...somebody please jack it up to 0.80 again...I liked it there better.
I saw an infomercial for the Slim 'n Lift last night. I gotta get one of those. Ha ha. Maybe two.
It's almost safe to say that we've seen it all by this point.
I want dessert!
No worse than dental surgery without anesthesia.
Yes that must be it. Super duper pooper scooper.
No I guess not. I just wonder if we will have to wait another 14 months (or whatever) for the next one.
Who knows, but it strikes me as an odd choice to put out this particular piece of news after such a long hiatus.
I didn't say whether or not it would happen, I was just saying that is what I think needs to happen.
Looks like Mr. Jarvis has some good experience in this area. What we need to see though, is for the company to get caught up with their financial filings and then tell us what the heck has been going on.
Excellent! We are all going nowhere fast together. This is like a bad reality TV show...<g>
A celebrity what? Endsorement? My end is sore from ICTL but not sure if it was a celebrity. I did not get a good look at the perp.
Ha ha. Just kidding.
Pricing an offering at $1 when the stock is at 1.37 indicates to me that the company was on the receiving end of the financing terms and not negotiating from a position of strength. It's also possible that this financing will enable shorts to cover at a bargain price. I don't know that's the case, just speculating, I am watching from the sidelines.
Nice going, Tim! Who knows, maybe we will hear something this week. After all Christmas is coming and we've been fairly good...compared to the banksters we've been angelic!
Helicos BioSciences Corporation Announces $6.4 Million Registered Direct Offering
Press Release Source: Helicos BioSciences On Tuesday December 15, 2009, 5:52 pm EST
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS - News) announced today that it has priced a registered direct offering of 6.4 million units, at a price of $1.00 per unit, for gross proceeds of $6.4 million before deducting underwriting discounts and commissions and estimated offering expenses. Each unit consists of one share of the company’s common stock and a warrant to buy 0.65 of a share of the company’s common stock. The warrants will be exercisable for a period of five years beginning six months after issuance, at an exercise price of $1.4385 per share. The closing of the offering is expected to take place on or about December 21, 2009, subject to the satisfaction of customary closing conditions. Thomas Weisel Partners LLC is acting as the sole book-running manager for the offering.
The company intends to use the net proceeds of the offering to fund its research and development efforts, and for general corporate purposes, including working capital.
The securities described above are being offered by Helicos BioSciences Corporation pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission. The offering may be made only by means of the prospectus supplement and the related prospectus relating to the offering, copies of which may be obtained, when available, from Thomas Weisel Partners LLC by mail at One Montgomery Street, San Francisco, California 94104 or by telephone at (415) 364-2720.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Helicos BioSciences:
Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing, tSMS(TM), technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of two $1,000 genome grants and committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800. For more information, please visit www.helicosbio.com.
Oh I was up quite a bit at one point so no, that is not my understanding. My understanding is that not using protective stops can be expensive. That said, the dead horse tells me that he is grateful that you are taking a break for the holidays.
We will see. If the stock continues the trajectory of the last two days it should only take until Wednesday for it to become a profitable position for me. <g>
When was the last time you heard me say that this stock is a buy? Being a stuckholder is not the same as being an advocate...or a detractor, for that matter.
With no financials and therefore no visibility into the company there is no reason why anyone would buy it now. I don't think that is a permanent condition unless they are planning to take the company private. Assuming that they make good on their commitment to bring financials up to date, we will then have some basis for making valuation assessments.
Why would we lie about still being in this one? For bragging rights? Now I've heard it all. Still...it could be worse. Like having Nancy Duitch for a CEO. I guess it's all relative...
Did you just figure that out now? And I thought I was slow...
No need to panic. 6800 shares traded at 0.20. It was only the last trade of the session of 1000 shares that was done at ten cents. The smart ones left in a panic a long time ago.
Bulk tonnage will make this a mine, imo, but we will have to see what the market thinks. The targets identified for 2010 indicate that RSH could get a lot bigger.
Well there would be a couple of problematic things under that scenario. It implies:
- he has access to inside information
- he acted on that information
Not saying it cannot happen but it sounds like an easy way to get into hot water fast with the regulatory agencies (assuming that they are not, as usual, fast asleep at the wheel). WMS has been selling down his position in EVG since leaving the BOD. He is listed as in insider in something like 17 companies. I continue to suspect that his activity has nothing to do with anything other than his own PF management. I sure wish we could get some news so we would have something substantial to talk about. This steady diet of rumor and innuendo is about as satisfying as eating one potato chip for lunch. <g>
bd - if he knows "something" then why would GPD.v have exercised their right to participate in the latest PP?
tsl
I have a call in to GPD.v to see if I can find out more about what is going on. It seems odd that WMS would be selling stock since they exercised their right to participate in the latest EVG PP. I suspect that WMS is selling shares from his own personal holdings and not from what GPD.v got by optioning the property to EVG or through the subsequent PPs. Should know more later today.